Discovering naturally processed antigenic determinants that confer protective T cell immunity

Pavlo Gilchuk,1 Charles T. Spencer,1 Stephanie B. Conant,1 Timothy Hill,1 Jennifer J. Gray,1 Xinnan Niu,1 Mu Zheng,1 John J. Erickson,1 Kelli L. Boyd,1 K. J. Jill McAfee,1 Carla Oseroff,2 Sine R. Hadrup,3 Jack R. Bennink,4 William Hildebrand,5 Kathryn M. Edwards,6 James E. Crowe Jr.,1,6 John V. Williams,1,6 Søren Buus,7 Alessandro Sette,2 Ton N.M. Schumacher,8 Andrew J. Link,1,9 and Sebastian Joyce1

1Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 2Centre for Infectious Diseases, Allergy and Asthma Research, The Jolli Institute of Allergy and Immunology, La Jolla, California, USA. 3Centre for Cancer Immunotherapy, Department of Haematology, Herlev Hospital, Herlev, Denmark. 4Laboratory of Viral Diseases, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA. 5Department of Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA. 6Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 7Laboratory of Experimental Immunology, University of Copenhagen, Copenhagen, Denmark. 8Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 9Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

CD8+ T cells (TCD8) confer protective immunity against many infectious diseases, suggesting that microbial TCD8 determinants are promising vaccine targets. Nevertheless, current T cell antigen identification approaches do not discern which epitopes drive protective immunity during active infection — information that is critical for the rational design of TCD8-targeted vaccines. We employed a proteomics-based approach for large-scale discovery of naturally processed determinants derived from a complex pathogen, vaccinia virus (VACV), that are presented by the frequent representatives of four major HLA class I supertypes. Immunologic characterization revealed that many previously unidentified VACV determinants were recognized by smallpox-vaccinated human peripheral blood cells in a variegated manner. Many such determinants were recognized by HLA class I–transgenic mouse immune TCD8 too and elicited protective TCD8 immunity against lethal intranasal VACV infection. Notably, efficient processing and stable presentation of immune determinants as well as the availability of naive TCD8 precursors were sufficient to drive a multifunctional, protective TCD8 response. Our approach uses fundamental insights into T cell epitope processing and presentation to define targets of protective TCD8 immunity within human pathogens that have complex proteomes, suggesting that this approach has general applicability in vaccine sciences.

Introduction

Vaccination is an effective approach to prevent infectious diseases. The majority of current vaccines consists of live, attenuated, or inactivated pathogens that were developed in the past by empirical approaches (1). Understanding vaccine-mediated correlates of immunity is critical for the rational design of novel pathogen-free vaccines against diseases caused by complex pathogens — such as malaria, tuberculosis, or HIV/AIDS, for which no effective vaccine currently exists — or to improve the safety and/or efficacy of existing vaccines (1–6).

CD8+ T cells (TCD8) play a critical role in conferring protective immunity against many infectious diseases, including those caused by respiratory viruses (7–11), cytomegalovirus (12), HIV (13), Plasmodium spp. (14, 15), and M. tuberculosis (16, 17). A key role for TCD8 immunity has also been established for the safety of smallpox vaccination in nonhuman primates (18) and humans (19). Therefore, microbial T cell epitope-based vaccines can complement current efforts to develop safe and effective antibody-targeted subunit vaccines.

Identification of immune TCD8 targets is a complicated task, because of MHC class I polymorphism and the ability to generate numerous potential epitopes from complex microbial proteomes for TCD8 appraisal. Computational epitope prediction in combination with TCD8 recognition assays is one solution to this quandary (20). This approach has identified numerous immune epitopes from different pathogens (http://www.iedb.org/). In addition, to elucidate the protective potential of TCD8 immunity, different correlates — such as the response magnitude (21), epitope immunogenicity, binding affinity (22), p/MHC stability (23), and recognition potency (24) as well as the ability to generate multifunctional effector response (25) and long-lived memory response (26) — have been comprehensively evaluated.

Vaccinia virus (VACV; ~200 proteins) is widely used as a model to study TCD8 responses to pathogens with complex proteomes. Interrogation of computationally predicted epitopes revealed that humans and mice recognize numerous epitopes by VACV-immune TCD8; humans recognize these epitopes in a variegated, i.e., partially overlapping, manner (27–31). Nevertheless, due to the current limitations of bioinformatics prediction approaches, identification of viral determinants that are efficiently presented in vivo and initiate protective TCD8 responses remains a challenge. In addition, the complexity of antimicrobial TCD8 responses (27–31) severely limits the screening of even known immune determinants for protective efficacy. Hence, only limited preclinical mouse studies have addressed...
rally processed, thereby narrowing the search for potential vaccine targets to those determinants that are efficiently presented during an infection (38). While only a few such epitopes have been evaluated for immune recognition (32, 37), none were ever interrogated for their protective potential. Therefore, it remains unclear whether the proteomics approach is superior for TCD8 epitope discovery over currently existing computational approaches and whether eluted peptides inform relevant vaccine targets.

In this study, we used VACV as a model, because a critical role has been attributed to TCD8 in conferring protective immunity against lethal respiratory VACV infection (10, 11). Using data from a comprehensive proof-of-principle study for the identification of potent TCD8 targets from a complex virome, we report large-scale discovery and immunologic characterization of naturally processed antigenic determinants of VACV that are presented by five frequent HLA class I allotypes that represent four major class I supertypes. Additionally, we provide direct evidence that naturally processed epitopes inform targets for TCD8-based protective immunity. Our strategy, in which fundamental insights into T cell epitope processing and presentation were used to define targets of protective TCD8 immunity, should have general applicability in vaccine sciences.

Results

Numerous VACV-derived determinants are naturally processed and presented by HLA class I molecules. Recognition of infected cells by TCD8 relies on efficient presentation of microbial determinants. We used a proteomics approach coupled with functional studies to identify and characterize naturally processed HLA class I–restricted determinants presented during active poxvirus infection (Figure 1). HeLa cells expressing soluble HLA-A*02:01 (aA2), -B*07:02 (aB7), -B35:01 (aB35), -A01:01 (aA1), or -B45:01 (aB45) molecules were infected with VACV, and associated peptides were eluted from class I molecules and fractionated by reversed-phase chromatography. In-line microcapillary HPLC-electrospray ionization tandem mass spectrometry (LC-MS/MS) of each eluted peptide fraction resulted in the acquisition of a large number of spectra (data not shown). Those that contained 9–11 amino acid residues and conformed to the canonical A2 and B7 binding motifs were validated using the corresponding synthetic peptide spectra and considered naturally processed class I–restricted determinants. That these are TCD8 epitopes is ascertained by functional assays and dual p/class I tetramer staining. Additionally, the protective potential of the TCD8 epitopes is tested in peptide vaccination and a respiratory VACV challenge model.
The comparative proteome searches identified 581 sA2- and 132 sB7-associated peptides that were expressed only by VACV-infected but not uninfected cells; of those, 109 A2- and 65 B7-restricted peptide sequences correlated with the MS/MS spectra’s fragment ion data with high confidence (see Methods, Supplemental Figure 1, and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI67388DS1) and, hence, were selected for synthesis and further material available online with this article; doi:10.1172/JCI67388DS1) and, hence, were selected for synthesis and further analysis. Similar analysis identified numerous naturally processed viral peptides eluted from sA1, sB35, and sB45 monolayers as well (our unpublished observations).

Mass spectrometry was performed with a low-resolution instrument (LTQ ion trap), which made data analysis challenging. Hence, synthetic peptides corresponding to the amino acid sequences of naturally processed peptides were analyzed by LC-MS/MS for spectral validation of each eluted peptide. For this purpose, the spectrum of the eluted peptide was qualitatively compared to that of the corresponding synthetic peptide. We found that the MS/MS spectra of most of the eluted peptides were similar to those of the corresponding synthetic peptides (Supplemental Figure 1 and data not shown), confirming the identity of the naturally processed peptides.

Comparison to the VACV proteome revealed that the naturally processed peptides were derived from all functional and kinetic classes of VACV proteins, with multiple determinants emerging from several ORFs (Supplemental Table 1), consistent with previous reports (28). Importantly, many known immune epitopes reported from algorithm-predicted determinants were also identified as naturally processed (Supplemental Table 1), indicating that the proteomics approach can be used for the discovery of TCD8 targets. Critically, however, we also identified dozens of determinants that would not be predicted to be TCD8 epitopes based upon the bioinformatics approach alone, many of which we validated as bona fide TCD8 targets (see below). Thus, we found from this thorough, large-scale analysis that, during VACV infection, a large and diverse array of naturally processed viral determinants was presented by representative members of the four most frequent HLA class I supertypes — i.e., A2 (A2), B7 (B7, B35), A1 (A1), and B44 (B45).

Many novel naturally processed determinants are recognized by human TCD8. We next ascertained whether viral peptides eluted from infected HeLa cells expressing soluble HLA class I molecules inform relevant targets for immune recognition during a natural infection in humans. Hence, the TCD8 response to a peptide panel (defined below) was evaluated using PBMCs from smallpox-vaccinated volunteers: 6 B7- or 7 A2-positive volunteers, either prior to (3 of each HLA type) or after DryVax vaccination (Supplemental Table 2). Because the frequency of VACV-specific TCD8 in humans is very low after vaccination (39, 40), epitope-specific TCD8 from PBMCs were expanded ex vivo prior to the assay. The peptide panel interrogated consisted of 83 B7- and 152 A2-restricted determinants (Supplemental Table 3); 65 B7- and 109 A2-restricted peptides were novel determinants found in this study, and the remainder was selected from previous reports (http://www.iedb.org/).

To ascertain whether the IFN-γ response to the naturally processed peptides was TCD8 derived, a panel of p/class I tetramers was prepared and their binding to ex vivo–expanded PBMCs was quantified. The peptide panel interrogated consisted of 83 B7- and 152 A2-restricted determinants (Supplemental Table 3); 65 B7- and 109 A2-restricted peptides were novel determinants found in this study, and the remainder was selected from previous reports (http://www.iedb.org/).

Two complementary assays — IFN-γ ELISpot and dual fluorochrome-conjugated p/class I tetramer staining approach — were used to determine the activity of the peptide panel. Data from the IFN-γ ELISpot assay revealed that each vaccinated individual showed only a partially overlapping, variegated recognition of the naturally processed determinant panel (Table 1).

To ascertain whether the IFN-γ response to the naturally processed peptides was TCD8 derived, a panel of p/class I tetramers was prepared and their binding to ex vivo–expanded PBMCs was quantified. The peptide panel interrogated consisted of 83 B7- and 152 A2-restricted determinants (Supplemental Table 3); 65 B7- and 109 A2-restricted peptides were novel determinants found in this study, and the remainder was selected from previous reports (http://www.iedb.org/).

**Table 1**

Summary of immune epitopes identified in smallpox-vaccinated B7 volunteers

<table>
<thead>
<tr>
<th>Peptide sequence</th>
<th>Volunteers&lt;sup&gt;a&lt;/sup&gt;</th>
<th>V003</th>
<th>V111</th>
<th>V150</th>
<th>V154</th>
<th>V155</th>
<th>V158</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Novel immune epitopes identified in this study</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FYEGGKVF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FPRSMSLIF</td>
<td>222</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPSNHILL</td>
<td>291</td>
<td>823&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FKPDVFVSF</td>
<td>534&lt;sup&gt;c&lt;/sup&gt;</td>
<td>539&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPRDAIRFL</td>
<td>367&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPNQHHTIDL</td>
<td>576&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APASSLPLAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FPSVFINPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VPIITGSKIL</td>
<td>158</td>
<td>9,074</td>
<td>278</td>
<td>736</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YPSNKNYE</td>
<td>144</td>
<td>8,701</td>
<td>238</td>
<td>1,383</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LPSNVEIKAI</td>
<td></td>
<td>1,317</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPKYLEIEI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPKXYBMYALL</td>
<td>291</td>
<td>1,725</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPSVLKILL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Known immune epitopes also found as naturally processed in this study</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPSTRNFELL</td>
<td>624</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Known immune epitopes not found as naturally processed in this study</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TVADVRHCL</td>
<td>1,226&lt;sup&gt;c&lt;/sup&gt;</td>
<td>291</td>
<td>2,588&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td>165</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPMLSRSTII</td>
<td>985&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPAYKINTL</td>
<td>157&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPRLYHTVM</td>
<td>257&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>The HLA class I allotype for each donor is provided in Supplemental Table 2. <sup>b</sup>The numbers of spot-forming cells over background per million PBMCs that secrete IFN-γ in response to individual peptides are presented; responses are considered positive only if spot-forming cells per million PBMCs were at least 100 over background. <sup>c</sup>Epitopes also found as positive in tetramer binding assay.

The comparative proteome searches identified 581 sA2- and 132 sB7-associated peptides that were expressed only by VACV-infected but not uninfected cells; of those, 109 A2- and 65 B7-restricted peptide sequences correlated with the MS/MS spectra’s fragment ion data with high confidence (see Methods, Supplemental Figure 1, and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI67388DS1) and, hence, were selected for synthesis and further study. Similar analysis identified numerous naturally processed VACV peptides eluted from sA1, sB35, and sB45 molecules as well (our unpublished observations).

Mass spectrometry was performed with a low-resolution instrument (LTQ ion trap), which made data analysis challenging. Hence, synthetic peptides corresponding to the amino acid sequences of naturally processed peptides were analyzed by LC-MS/MS for spectral validation of each eluted peptide. For this purpose, the spectrum of the eluted peptide was qualitatively compared to that of the corresponding synthetic peptide. We found that the MS/MS spectra of most of the eluted peptides were similar to those of the corresponding synthetic peptides (Supplemental Figure 1 and data not shown), confirming the identity of the naturally processed peptides.

Comparison to the VACV proteome revealed that the naturally processed peptides were derived from all functional and kinetic classes of VACV proteins, with multiple determinants emerging from several ORFs (Supplemental Table 1), consistent with previous reports (28). Importantly, many known immune epitopes reported from algorithm-predicted determinants were also identified as naturally processed (Supplemental Table 1), indicating that the proteomics approach can be used for the discovery of TCD8 targets. Critically, however, we also identified dozens of determinants that would not be predicted to be TCD8 epitopes based upon the bioinformatics approach alone, many of which we validated as bona fide TCD8 targets (see below). Thus, we found from this thorough, large-scale analysis that, during VACV infection, a large and diverse array of naturally processed viral determinants was presented by representative members of the four most frequent HLA class I supertypes — i.e., A2 (A2), B7 (B7, B35), A1 (A1), and B44 (B45).

Many novel naturally processed determinants are recognized by human TCD8. We next ascertained whether viral peptides eluted from infected HeLa cells expressing soluble HLA class I molecules inform relevant targets for immune recognition during a natural infection in humans. Hence, the TCD8 response to a peptide panel (defined below) was evaluated using PBMCs from smallpox-vaccinated volunteers: 6 B7- or 7 A2-positive volunteers, either prior to (3 of each HLA type) or after DryVax vaccination (Supplemental Table 2). Because the frequency of VACV-specific TCD8 in humans is very low after vaccination (39, 40), epitope-specific TCD8 from PBMCs were expanded ex vivo prior to the assay. The peptide panel interrogated consisted of 83 B7- and 152 A2-restricted determinants (Supplemental Table 3); 65 B7- and 109 A2-restricted peptides were novel determinants found in this study, and the remainder was selected from previous reports (http://www.iedb.org/).

To ascertain whether the IFN-γ response to the naturally processed peptides was TCD8 derived, a panel of p/class I tetramers was prepared and their binding to ex vivo–expanded PBMCs was quantified. p/class I monomers only formed with ~55% of the total peptides due to poor binding of some low-affinity peptides to the cognate class I molecule (see t<sub>1/2</sub> in Supplemental Table 1 and data not shown), thereby narrowing the TCD8 specificities that could be probed. p/class I tetramer staining confirmed that the IFN-γ response was indeed generated by B7- or A2-restricted TCD8 (Table 1, Supplemental Figure 2, and Supplemental Table 4). Notably, immunologic screening of naturally processed peptides revealed that many novel immune epitopes were recognized by human PBMCs obtained from smallpox vaccinees in addition to those reported from algorithm-based approaches (Table 1 and Supplemental Table 4). Most importantly, these results indicate that the eluted viral determinants identified by our proteomics approach inform relevant targets for TCD8 recognition.

TCD8 from HLA class I–transgenic mice recognize naturally processed determinants. We used a HLA class I–transgenic mouse model to define the qualitative and quantitative features of VACV-specific TCD8 response reactive to the eluted, naturally processed...
postinoculation (p.i.). Robust expansion of epitope-specific TCD8 from VACV-immune splenocytes but not from naive splenocytes was observed (Supplemental Figure 5), indicating that all antigen-specific reactivity detected (Figure 2) was specifically elicited in response to VACV in vivo.

In an independent approach, we assessed whether the TCD8-reactive peptides discovered by proteomics are actual epitopes generated through processing and presentation from cognate VACV proteins in vivo. For this purpose, B7+ mice were immunized with individual VACV-derived proteins containing targeted epitope sequences. Nine recombinant proteins containing the ten immune determinants (two of which are D1R derived; Supplemental Figure 6) were produced in E. coli and purified. B7+ mice were primed and boosted (i.p.) with individual proteins formulated with the natural killer T cell ligand \( \alpha \)-galactosylceramide (Supplemental Figure 7A), which is known to function as an adjuvant (42–45). All proteins were immunogenic when formulated with \( \alpha \)-galactosylceramide and induced a robust systemic response, as judged by detection of epitope-specific TCD8 with p/B7.2 tetramers at day 6 after boost (Supplemental Figure 7B, Supplemental Figure 8, and data not shown). Moreover, such protein-elicted TCD8 functionally responded to restimulation with antigenic peptide, which induced the expression of intracellular IFN-\( \gamma \) and mobilized CD107a — a marker for degranulation — to the plasma membrane (Supplemental Figure 7C). Hence, we conclude that all the tested immune determinants are processed and presented from the cognate antigens in vivo.

To determine whether the stability of epitope presentation influenced TCD8 recognition, the half-life of each of the naturally processed epitopes in vivo. For this purpose, B7+ mice were primed and boosted (i.p.) with individual proteins formulated with the natural killer T cell ligand \( \alpha \)-galactosylceramide (Supplemental Figure 7A), which is known to function as an adjuvant (42–45). All proteins were immunogenic when formulated with \( \alpha \)-galactosylceramide and induced a robust systemic response, as judged by detection of epitope-specific TCD8 with p/B7.2 tetramers at day 6 after boost (Supplemental Figure 7B, Supplemental Figure 8, and data not shown). Moreover, such protein-elicated TCD8 functionally responded to restimulation with antigenic peptide, which induced the expression of intracellular IFN-\( \gamma \) and mobilized CD107a — a marker for degranulation — to the plasma membrane (Supplemental Figure 7C). Hence, we conclude that all the tested immune determinants are processed and presented from the cognate antigens in vivo.

To determine whether the stability of epitope presentation influenced TCD8 recognition, the half-life of each of the naturally processed p/class I complexes was quantified. We found that most of the immune determinants identified in this study were stably presented by their cognate class I molecules (Table 2 and Supplemental Tables 1 and 5). Together the data suggest that the antigenic determinants identified here are potential targets for protective TCD8 responses during a natural infection.

Individual TCD8 specificities targeting naturally processed epitopes exhibit similar phenotype, functional competence, and homing pattern. The immunologic rationale for the selection of potent vaccine targets among numerous determinants should rely on their ability to elicit
Most immune TCD8 specificities elicited against efficiently presented epitopes contribute to protection against VACV. Efficient recruitment of naive antigen-specific pTCD8 that can evolve into effector and memory cells is required to generate protective immunity. Hence, to determine the extent of TCD8 recruitment upon VACV infection, we compared frequencies of naive and immune TCD8 recognizing naturally processed epitopes. For this purpose, pTCD8 against the 10 characterized immune epitopes were enumerated in naive B7tg mice after successive TCD8 and p/B7.2 tetramer-based enrichments (Supplemental Figure 11). We found that the VACV epitope-specific pTCD8 frequencies ranged from approximately 126 (E2L 216–224) to approximately 6,104 (L4R 37–45) per mouse, which corresponds to 17 and 731 pTCD8 per 10⁶ naïve TCD8, respectively (Figure 4). Of the 10 epitopes, only 3—namely, the highly dominant A34R 82–90 (mean ~2,465 pTCD8 per mouse), dominant D1R 808–817 (mean ~1,892 pTCD8 per mouse), and subdominant L4R 37–45 (mean ~6,104 pTCD8 per mouse)—were higher than those reported for the most frequent pTCD8—e.g., MCMV M45:Db (~1,500 pTCD8 per mouse) and VACV B8R:Kb (~1,400 pTCD8 per mouse) epitopes (47–51). B7tg mice contain only about a third of the total TCD8 (~7 × 10⁶ to 8 × 10⁶ TCD8 per mouse; data not shown) ordinarily generated by C57BL/6 mice (~17 × 10⁶ TCD8 per mouse; ref. 51), perhaps because the former expresses only one class I allele, as they do not express mouse H2 class I molecules. Hence, the normalized pTCD8 frequency per 10⁶ TCD8 appears abnormally high. Notable, for 3 dominant (A34R 82–90, D1R 808–817, B8R 70–79) and 4 subdominant (J6R 303–311, D1R 808–817, B8R 70–79) and p/B7.2 TCD8, respectively (Figure 2D and Figure 4). This result suggests proportional expansion of the corresponding naive pTCD8 during infection.

Surprisingly, the naive pTCD8 frequency for the 3 remaining subdominant determinants (L4R 37–45, D5R 375–383, F4L 14–14) was not concordant with the magnitude of the primary TCD8 response (Figure 2D and Figure 4), suggesting that these determinants are less potent TCD8 targets. To test this prediction, all 10 immune epitopes were individually formulated with anti-CD40 antibody plus poly(I:C) as adjuvant (see Methods) and used to immunize mice, an approach reported to efficiently elicit TCD8 responses (52). Tracking of blood TCD8 with p/B7.2 tetramers revealed that some determinants, including the dominant B8R 70–79 epitope, were not immunogenic, even after repeated vaccinations (data not shown). This lack of immunogenicity, previously described for some H2Kb-restricted immune determinants (22), was not predicted by the frequency of naive or VACV-immune TCD8. Critically, nonetheless, when mice were primed with in vitro-maturated, peptide-loaded DCs, all 10 epitopes elicited robust epitope-specific secondary responses, which accounted for 4% to 92% of total blood TCD8 (Figure 5, A and B). Thus, our results suggest that many of the available precursor specificities, including those for subdominant TCD8, have the potential to be efficiently recruited to the immune response when the cognate antigenic determinant is efficiently presented.

We next determined the protective potential of individual TCD8 specificities recognizing naturally processed determinants. For this, the above epitope-vaccinated mice were lethally challenged by i.n. VACV; these mice were observed during the next 6 days for morbidity and weight loss, and, on day 6 after challenge, lung viral burdens were measured as well. To ensure elicitation of robust

Table 2
Summary of immune epitopes identified in B7 transgenic mice

<table>
<thead>
<tr>
<th>Sequencea</th>
<th>ORF</th>
<th>( t_{\text{iz}} ) (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FPKNDVFSF</td>
<td>BBR 70–79</td>
<td>5.2</td>
</tr>
<tr>
<td>SPSNHILL</td>
<td>A3L 100–200</td>
<td>5.46</td>
</tr>
<tr>
<td>LPKEYSSL</td>
<td>DSR 375–383</td>
<td>7.44</td>
</tr>
<tr>
<td>FPYEGGKVF</td>
<td>E9L 326–334</td>
<td>6.17</td>
</tr>
<tr>
<td>RPRDAIRFL</td>
<td>E2L 216–224</td>
<td>4.81</td>
</tr>
<tr>
<td>FPRSMLSIF</td>
<td>L4R 37–45</td>
<td>6.08</td>
</tr>
<tr>
<td>RPNQHHTIDL</td>
<td>N2L 104–113</td>
<td>4.73</td>
</tr>
<tr>
<td>FPTNTLTSF</td>
<td>I6L 237–245</td>
<td>1.52</td>
</tr>
</tbody>
</table>

Known immune epitopes also found as naturally processed in this study

<table>
<thead>
<tr>
<th>Sequencea</th>
<th>ORF</th>
<th>( t_{\text{iz}} ) (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RPSTRNFEFL</td>
<td>D1R 808–817</td>
<td>2.93</td>
</tr>
<tr>
<td>LPRPVDTHRL</td>
<td>A34R 82–90</td>
<td>1.52</td>
</tr>
</tbody>
</table>

Known immune epitopes not found as naturally processed in this study

<table>
<thead>
<tr>
<th>Sequencea</th>
<th>ORF</th>
<th>( t_{\text{iz}} ) (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPAYIRNLT</td>
<td>J6R 303–311</td>
<td>5.44</td>
</tr>
<tr>
<td>HPRIVATVM</td>
<td>D1R 808–817</td>
<td>6.47</td>
</tr>
<tr>
<td>APHNPMRFV</td>
<td>F4L 14–14</td>
<td>8.81</td>
</tr>
<tr>
<td>RPMVLRSTI</td>
<td>O1L 225–244</td>
<td>5.31</td>
</tr>
</tbody>
</table>

Identified by IFN-\( \gamma \) ELISpot assay. \( \text{Epitopes also found as positive in tetramer binding assay.} \)}
TCID8 responses, 1 out of 2 vaccination schemes (Figure 5A) determined above as optimal for a given epitope was applied. We found that nonvaccinated mice were unable to control VACV replication (~10^8 pfu VACV per lungs), and all succumbed to the disease by day 7 (Figure 5, C and E, Supplemental Figure 12). On the other hand, vaccination with 9 out of the 10 tested determinants resulted in various degrees of protection, as judged by disease severity, weight loss, and lung viral load reduction (Figure 5, C–E). Targeting TCID8 against 2 dominant (B8R70–79, A3L192–200) and subdominant (ASL192–200) TCID8 specificities identified in VACV-immune spleens acquired similar effector (CD44^hiCD62L^GzmB^KLRG1^hi) and memory (CD44^hiCD62L^CD127^hi) phenotypes. Representative data for 3 TCID8 specificities of 6 measured are shown. Numbers represent the percentage of p/B7 tetramer^+ cells within TCID8 gate (top row) or the percentage of p/B7 tetramer^+ TCID8 with indicated phenotype. (C and D) Multifunctionality of dominant and subdominant TCID8 detected in immune spleens after ex vivo restimulation with peptide. Data are representative of at least 2 independent experiments. Numbers in C represent the percentage of IFN-γ/CD107a^+ cells within the TCID8 gate (top row) or the percentage of IFN-γ/CD107a^+ TCID8 expressing the indicated cytokines (middle and bottom rows). Error bars in D represent mean ± SD of the assay replicates (n = 3–5). (E) Broad TCR Vα usage within individual TCID8 specificity. Bar segments indicate the proportion of TCRβ clonotype within the indicated p/B7 tetramer^+ TCID8 spleen cells. Note that priming with VACV proteins followed by viral challenge enhanced the 4 low-frequency TCID8. (F) Wide tissue distribution of VACV-specific TCID8. Bar segments indicate the proportion of the indicated specificity within the 10 p/B7 tetramer^+ TCID8 measured. Data are representative of 2 independent experiments (n = 5).

Figure 3
Individual TCID8 exhibit similar phenotype, functional competence, and homing pattern. (A) Experimental design. B7^tg mice were inoculated i.p. with 2 × 10^5 pfu VACV, and the TCID8 response was characterized on day 7. (B) Dominant (D1R808–817, B8R70–79) and subdominant (ASL192–200) TCID8 specificities identified in VACV-immune spleens acquired similar effector (CD44^hiCD62L^GzmB^KLRG1^hi) and memory (CD44^hiCD62L^CD127^hi) phenotypes. Representative data for 3 TCID8 specificities of 6 measured are shown. Numbers represent the percentage of p/B7 tetramer^+ cells within TCID8 gate (top row) or the percentage of p/B7 tetramer^+ TCID8 with indicated phenotype. (C and D) Multifunctionality of dominant and subdominant TCID8 detected in immune spleens after ex vivo restimulation with peptide. Data are representative of at least 2 independent experiments. Numbers in C represent the percentage of IFN-γ/CD107a^+ cells within the TCID8 gate (top row) or the percentage of IFN-γ/CD107a^+ TCID8 expressing the indicated cytokines (middle and bottom rows). Error bars in D represent mean ± SD of the assay replicates (n = 3–5). (E) Broad TCR Vα usage within individual TCID8 specificity. Bar segments indicate the proportion of TCRβ clonotype within the indicated p/B7 tetramer^+ TCID8 spleen cells. Note that priming with VACV proteins followed by viral challenge enhanced the 4 low-frequency TCID8. (F) Wide tissue distribution of VACV-specific TCID8. Bar segments indicate the proportion of the indicated specificity within the 10 p/B7 tetramer^+ TCID8 measured. Data are representative of 2 independent experiments (n = 5).

TCID8 responses, 1 out of 2 vaccination schemes (Figure 5A) determined above as optimal for a given epitope was applied. We found that nonvaccinated mice were unable to control VACV replication (~10^8 pfu VACV per lungs), and all succumbed to the disease by day 7 (Figure 5, C and E, Supplemental Figure 12). On the other hand, vaccination with 9 out of the 10 tested determinants resulted in various degrees of protection, as judged by disease severity, weight loss, and lung viral load reduction (Figure 5, C–E). Targeting TCID8 against 2 dominant (B8R70–79, A3L192–200) and subdominant (ASL192–200) TCID8 specificities identified in VACV-immune spleens acquired similar effector (CD44^hiCD62L^GzmB^KLRG1^hi) and memory (CD44^hiCD62L^CD127^hi) phenotypes. Representative data for 3 TCID8 specificities of 6 measured are shown. Numbers represent the percentage of p/B7 tetramer^+ cells within TCID8 gate (top row) or the percentage of p/B7 tetramer^+ TCID8 with indicated phenotype. (C and D) Multifunctionality of dominant and subdominant TCID8 detected in immune spleens after ex vivo restimulation with peptide. Data are representative of at least 2 independent experiments. Numbers in C represent the percentage of IFN-γ/CD107a^+ cells within the TCID8 gate (top row) or the percentage of IFN-γ/CD107a^+ TCID8 expressing the indicated cytokines (middle and bottom rows). Error bars in D represent mean ± SD of the assay replicates (n = 3–5). (E) Broad TCR Vα usage within individual TCID8 specificity. Bar segments indicate the proportion of TCRβ clonotype within the indicated p/B7 tetramer^+ TCID8 spleen cells. Note that priming with VACV proteins followed by viral challenge enhanced the 4 low-frequency TCID8. (F) Wide tissue distribution of VACV-specific TCID8. Bar segments indicate the proportion of the indicated specificity within the 10 p/B7 tetramer^+ TCID8 measured. Data are representative of 2 independent experiments (n = 5).

TCID8 responses, 1 out of 2 vaccination schemes (Figure 5A) determined above as optimal for a given epitope was applied. We found that nonvaccinated mice were unable to control VACV replication (~10^8 pfu VACV per lungs), and all succumbed to the disease by day 7 (Figure 5, C and E, Supplemental Figure 12). On the other hand, vaccination with 9 out of the 10 tested determinants resulted in various degrees of protection, as judged by disease severity, weight loss, and lung viral load reduction (Figure 5, C–E). Targeting TCID8 against 2 dominant (B8R70–79, A3L192–200) and subdominant (ASL192–200) TCID8 specificities identified in VACV-immune spleens acquired similar effector (CD44^hiCD62L^GzmB^KLRG1^hi) and memory (CD44^hiCD62L^CD127^hi) phenotypes. Representative data for 3 TCID8 specificities of 6 measured are shown. Numbers represent the percentage of p/B7 tetramer^+ cells within TCID8 gate (top row) or the percentage of p/B7 tetramer^+ TCID8 with indicated phenotype. (C and D) Multifunctionality of dominant and subdominant TCID8 detected in immune spleens after ex vivo restimulation with peptide. Data are representative of at least 2 independent experiments. Numbers in C represent the percentage of IFN-γ/CD107a^+ cells within the TCID8 gate (top row) or the percentage of IFN-γ/CD107a^+ TCID8 expressing the indicated cytokines (middle and bottom rows). Error bars in D represent mean ± SD of the assay replicates (n = 3–5). (E) Broad TCR Vα usage within individual TCID8 specificity. Bar segments indicate the proportion of TCRβ clonotype within the indicated p/B7 tetramer^+ TCID8 spleen cells. Note that priming with VACV proteins followed by viral challenge enhanced the 4 low-frequency TCID8. (F) Wide tissue distribution of VACV-specific TCID8. Bar segments indicate the proportion of the indicated specificity within the 10 p/B7 tetramer^+ TCID8 measured. Data are representative of 2 independent experiments (n = 5).

TCID8 responses, 1 out of 2 vaccination schemes (Figure 5A) determined above as optimal for a given epitope was applied. We found that nonvaccinated mice were unable to control VACV replication (~10^8 pfu VACV per lungs), and all succumbed to the disease by day 7 (Figure 5, C and E, Supplemental Figure 12). On the other hand, vaccination with 9 out of the 10 tested determinants resulted in various degrees of protection, as judged by disease severity, weight loss, and lung viral load reduction (Figure 5, C–E). Targeting TCID8 against 2 dominant (B8R70–79, A3L192–200) and subdominant (ASL192–200) TCID8 specificities identified in VACV-immune spleens acquired similar effector (CD44^hiCD62L^GzmB^KLRG1^hi) and memory (CD44^hiCD62L^CD127^hi) phenotypes. Representative data for 3 TCID8 specificities of 6 measured are shown. Numbers represent the percentage of p/B7 tetramer^+ cells within TCID8 gate (top row) or the percentage of p/B7 tetramer^+ TCID8 with indicated phenotype. (C and D) Multifunctionality of dominant and subdominant TCID8 detected in immune spleens after ex vivo restimulation with peptide. Data are representative of at least 2 independent experiments. Numbers in C represent the percentage of IFN-γ/CD107a^+ cells within the TCID8 gate (top row) or the percentage of IFN-γ/CD107a^+ TCID8 expressing the indicated cytokines (middle and bottom rows). Error bars in D represent mean ± SD of the assay replicates (n = 3–5). (E) Broad TCR Vα usage within individual TCID8 specificity. Bar segments indicate the proportion of TCRβ clonotype within the indicated p/B7 tetramer^+ TCID8 spleen cells. Note that priming with VACV proteins followed by viral challenge enhanced the 4 low-frequency TCID8. (F) Wide tissue distribution of VACV-specific TCID8. Bar segments indicate the proportion of the indicated specificity within the 10 p/B7 tetramer^+ TCID8 measured. Data are representative of 2 independent experiments (n = 5).
A large literature supports an essential role for TCD8 in protective immunity against many infectious diseases. Notably, even pathogens with relatively small proteomes, e.g., influenza virus, generate broad TCD8 responses in humans (53), and those with large proteomes, e.g., VACV, elicit a more complex response (28, 29). Hence, we would predict the actual breadth of the TCD8 response to complex pathogens — such as Plasmodium or Mycobacterium spp., which surprisingly has never been determined — to be much more complex than those described so far. Moreover, in addition to limited knowledge of immune epitopes, the protective efficacy of individual TCD8 specificities elicited by vaccination has not been elucidated. Consequently, TCD8 protection studies were limited to a few readily detectable epitopes in mice. In contrast, attempts to achieve TCD8-targeted vaccination against complex pathogens in humans were rather empirical and have relied on elicitation of TCD8 with engineered vaccines without solid evidence for efficient presentation of the targeted antigenic determinant during infection (54, 55).

Bioinformatics/algorithm-based prediction for TCD8 epitope discovery, a generally accepted approach, resulted in identification of naturally processed allergens that are efficiently presented and recognized by immune TCD8, which may contribute to overall antiviral immunity during acute infection. Our results emphasize the proteomics approach for discovery of naturally processed HLA class I–restricted epitopes that are efficiently presented during infection with a complex pathogen as a viable method to identify targets of protective TCD8 immunity.

Discussion

The novelty of our work lies in the provision of direct evidence that identification of potent TCD8 targets for pathogens with complex proteomes requires discovery and comprehensive characterization of naturally presented antigenic determinants that are efficiently presented during infection. Hence, in this comprehensive proof-of-principle study, we first discovered naturally processed VACV determinants that are recognized by immune TCD8 and characterized their protective potential in mice. Such an approach in which in-depth insights into fundamental immunobiology of T cell epitopes was used to define targets of protective TCD8 immunity has a broad application, especially for the rational design of TCD8-based vaccines against disease agents with complex proteomes.

A large literature supports an essential role for TCD8 in protective immunity against many infectious diseases. Notably, even pathogens with relatively small proteomes, e.g., influenza virus, generate broad TCD8 responses in humans (53), and those with large proteomes, e.g., VACV, elicit a more complex response (28, 29). Hence, we would predict the actual breadth of the TCD8 response to complex pathogens — such as Plasmodium or Mycobacterium spp., which surprisingly has never been determined — to be much more complex than those described so far. Moreover, in addition to limited knowledge of immune epitopes, the protective efficacy of individual TCD8 specificities elicited by vaccination has not been elucidated. Consequently, TCD8 protection studies were limited to a few readily detectable epitopes in mice. In contrast, attempts to achieve TCD8-targeted vaccination against complex pathogens in humans were rather empirical and have relied on elicitation of TCD8 with engineered vaccines without solid evidence for efficient presentation of the targeted antigenic determinant during infection (54, 55).

Bioinformatics/algorithm-based prediction for TCD8 epitope discovery, a generally accepted approach, resulted in identification...
of numerous VACV-specific immune determinants. Surprisingly, using our proteomics approach, we identified numerous naturally processed and presented VACV epitopes that were not previously considered as potential TCD8 targets by algorithm prediction and, hence, were not tested for TCD8 recognition. Moreover, by subsequent testing of naturally processed determinants in vaccinated mice and humans, we found many novel immune epitopes, including dominant and subdominant ones. These findings provide evidence that prediction approaches have greatly underestimated the actual breadth of the TCD8 response to VACV. Thus, it is likely that discovery of immune epitopes for pathogens with larger proteomes using algorithms would not be feasible, due to the necessity for screening of large predicted epitope arrays for immune recognition and because currently available T cell assays, such as tetramer staining or ELISpot, albeit sensitive, are severely limited in their potential for high-throughput screening of T cell epitopes (56).

The sensitivity limits of the proteomics approach favor detection of stably presented and highly abundant MHC-associated determinants. Nevertheless, our work suggests that this approach is superior to other approaches because the search for potential vaccine targets is narrowed to those determinants that are efficiently presented during an actual infection. We identified 67 naturally processed B7-restricted antigenic determinants, from which 27 were stably presented by the cognate class I molecule. Ten stably presented determinants were recognized by immune TCD8 in B7tg mice, together covering nearly 50% of the overall anti-VACV TCD8 response. Seven out of the ten epitopes recognized by TCD8 were tested for protection; four of these conferred sufficient protection against lethal respiratory VACV infection. Collectively, approximately 6% of the eluted peptides, or approximately 15% of stably presented peptides, were recognized by immune TCD8 and elicited protective responses in vivo.

The human cell line used as the source of class I–bound peptides may underrepresent or overrepresent actual in vivo breadth of naturally processed and presented VACV determinants. We found one eluted epitope (L4R37–45) that was poorly presented during acute VACV infection and generated nonprotective response in epitope vaccination despite the high frequency of functional responders. Some naturally processed determinants of VACV reported previously were not found in this study. It is likely that the use of different cell lines, different multiplicity and kinetics of infection, and engineered soluble class I molecules to elute bound peptides may have resulted in the identification of nonoverlapping naturally processed determinants in different studies (32, 36). Some of the qualitative differences mentioned above may have arisen from differences in the activity of the class I peptide-loading complex that associated with soluble and membrane-bound class I molecule. Differences in proteasome activities, both constitutive and immunoproteasomes, in HeLa cells compared with those in professional antigen-presenting cells could have further confounded proteomics-based epitope discovery. Notwithstanding these limitations, because we have functionally characterized the eluted peptides, we believe that this is the first proof-of-principle study suggesting that naturally processed epitopes inform relevant targets for protective TCD8 responses from a microbe with a large proteome.

The protective potential of individual TCD8 specificities elicited during a natural infection or upon successful vaccination has remained underexplored. To elucidate the requirements for...
rational targeting of microbial TCD8 epitopes, VACV-immune TCD8 recognizing 10 naturally processed immune determinants of variable dominance were interrogated for phenotype, function, proliferation, and protective efficacy in B7γ mice. Surprisingly, we found that individual TCD8, regardless of their dominance, exhibited similar phenotype and functional competence. Moreover, protective efficacy of individual TCD8 specificities elicited by vaccination was discordant with the established dominance hierarchy. On the other hand, vaccination with a single dominant (B8R0.79) or subdominant (J6R0.03-311 and A3L192-200) determinant conferred sufficient protection from lethal respiratory VACV infection. Hence, naive precursors of both dominant and subdominant specificities efficiently evolved into multifunctional and protective immune responses upon epitope-targeted vaccination. These results provide the first comprehensive evidence to our knowledge that TCD8 dominance in acute infection does not inform the quality of the immune responders that confer protection. It rather reflects quantitative differences in the frequency of their naive precursors, as was noted by others as well (57). Importantly, we have shown that protection is achieved when targeted immune determinants are efficiently presented during viral infective cycle.

Notably, some epitopes (namely, B8R0.79-79) were immunogenic when mice were vaccinated with peptide-pulsed DCs but not with poly(I:C) plus anti-CD40 antibody, suggesting that the immunogenicity of epitopes depends on the form in which they are presented. In one instance, immunization scheme I — in which priming was performed with peptide formulated with poly(I:C) plus anti-CD40 antibody — resulted in a much more robust TCD8 response against F4L6-14 than that resulting from scheme II. Consequently, the former resulted in much better protection than the latter, which was essentially nonprotective (data not shown). Therefore, the vaccination scheme itself does not explain the difference in protection. Instead, we found that, to confer protection against lethal VACV challenge, it was critical to achieve a robust TCD8 response by epitope vaccination. Moreover, when immunogenic, we also discovered that individual TCD8 specificities, despite similar functional competence, exhibited varied protective efficacy in active VACV infection. Critically, this varied protection was not directly linked to TCD8 frequency elicited by vaccination: e.g., some responders at lower frequency (A3L192-200) were more protective than others elicited at higher frequency (F4L6-14), whereas some responders (L4R37-45) were not protective regardless of their frequency. It is likely that differential abundance of determinants and/or kinetics of their natural presentation define visibility of infected cells to cognate TCD8 in vivo, thus restricting protective responses to specificities that efficiently recognize infected cells. For example, we demonstrated that targeting the poorly presented immune determinant L4R37-45 failed to protect.

Taken together, our findings emphasize the discovery of naturally processed and efficiently presented immune determinants as a rational approach for the identification of protective TCD8 specificities from complex microbial proteomes. Importantly, such protective immune determinants — especially because some of these were commonly recognized by mouse and human immune cells (namely, B8R0.79, A3L192-200, and J6R0.03-311) and are highly conserved among poxviral, including variola, proteomes — are potential candidates for TCD8-targeted vaccine design. Application of the approach described herein could benefit discovery of vaccine targets against other human scourges such as malaria, tuberculosis, and HIV/AIDS.

### Methods

**Viruses.** The Western Reserve strain of VACV (ATCC, VR-119) was grown in and titrated with BSC-40 cells.

**Large-scale cell culture and VACV infection.** Soluble HLA class I (sA2.1 and sB7.2) production and harvest were as described previously (58). Briefly, approximately 1 x 10⁹ viable cells were inoculated with VACV (MOI 0.1). Supernatants containing approximately 0.3–4.2 mg/l sA2.1 and sB7.2 were collected at 24, 48, and 72 hours after inoculation.

**Isolation and fractionation of class I-associated peptides.** sA2 and sB7 were affinity purified using W6/32-bound protein A-Sepharose (GE Healthcare). Class I-associated peptide elution, separation, and reversed-phase HPLC purification were all performed as previously described (59).

**Mass spectrometry sequencing of eluted peptides.** Lyophilized fractions were resuspended in 0.1% formic acid and subjected to reversed-phase microcapillary LC-nanoESI-MS/MS analysis using an Agilent 1100 binary HPLC pump and an LTQ linear ion trap mass spectrometer 2.2 (Thermo Fisher). A fritless, microcapillary column (100-μm inner diameter) was packed with 10 cm of 5-μm C₁₈ reversed-phase material (Synergi 4μ Hydro RP80a, Phenomenex) as previously described (60). Reversed-phase HPLC–fractionated peptides were loaded onto the column equilibrated in buffer A (0.1% formic acid, 5% acetonitrile) using a LC-Packings autosampler. Flow splitting was used to reduce the HPLC flow rate from 200 μl per minute to 0.3 μl per minute as previously described (60, 61). Peptides from the microcapillary column were eluted directly into the linear ion LTQ mass spectrometer equipped with a microelectrospray source (James Hill Instrument Service). Peptides were eluted using a 60-minute linear gradient from 0% to 60% buffer B (0.1% formic acid, 80% acetonitrile) at a flow rate of 0.3 μl per minute. During the gradient, the eluted ions were analyzed by 1 full precursor MS scan (400–2,000 m/z), followed by 5 MS/MS scans of the 5 most abundant ions detected in the precursor MS scan while operating under dynamic exclusion. The program extractmz2 was used to generate the ASCII peak list and identify +1 or multiply charged precursor ions from the native mass spectrometry data file (62). Tandem spectra were searched with no protease specificity using SEQUEST-PVM (63) against a concatenated Human RefSeq protein database release (May 2005) (28,818 entries) and Vaccinia_WR_Copehagen protein database (760 entries). For multiply charged precursor ions (z ≥ 2), an independent search was performed on both the +2 and +3 mass of the parent ion. A weighted scoring matrix was used to select the most likely charge state of multiply charged precursor ions as previously described (64, 65). Data were processed and organized using the BIGCAT software analysis suite (64).

**Bioinformatics.** Candidate immune epitopes were selected based solely on their spectral characteristics, namely, (a) their presence in replicate samples (A2) or at multiple time points (A2 and B7); (b) high Cn score; and (c) independent visual confirmation of the mass spectrum. A search for public immune epitopes was conducted through the Immune Epitope Database (http://www.iedb.org/). Peptide conservation among other Orthopoxviridae members was performed using netBLAST search (NCBI).

**Volunteers.** Individuals (Supplemental Table 2) receiving the DryVax smallpox vaccine were identified and recruited into IRB-approved studies by S. Joyce or C. Oseroff and A. Sette (28). Peripheral blood was obtained by venipuncture, and PBMCs were isolated by centrifugation over Ficoll-Paque (GE Healthcare).

**Mice and infection.** B7γ and A2γ transgenic mice were previously described (66). These mice do not express the class Ia molecules H2Kb and Dα. To elicit primary TCD8 responses, 6- to 8-week-old mice were inoculated i.p. with approximately 2 x 10⁹ pfu VACV in sterile PBS. After 7 days, mononuclear cells were harvested from the various tissues and used for functional assays.

**ELISPOT.** Ten thousand to 300,000 cells were cocultivated with the appropriate peptide concentration or medium alone for 16 to 18 hours. IFN-γ
technical advance

secreted into the medium was quantified by ELISPot assay, as previously described, using 1–1.5 μg/ml anti-human IFN-γ (1-D1K, Mabtech) or anti-mouse IFN-γ (AN18, eBioscience) (67).

Statistics. ELISPot data were processed using Statistica software (StatSoft). Where indicated, data comparisons were performed using Prism version 4.0 (GraphPad Software). Multiple group comparisons were performed using 1-way ANOVA with Dunnett’s post-hoc test to compare epitope-vaccinated groups with mock. Comparisons between 2 groups were performed using Mann-Whitney test. P < 0.05 was considered significant.

Study approval. All mice were bred, maintained, and used in experiments in compliance with approved Institutional Animal Care and Use Committee regulations at Vanderbilt University. The Vanderbilt University and La Jolla Institute for Allergy and Immunology IRBs approved all studies involving human PBMCs. All volunteers provided consent per IRB protocol prior to blood collection.

Supplemental material. Additional data are available in the Supplemental Methods, supplemental tables, and supplemental figures, which are available online.

Acknowledgments. We dedicate this work to the memory of late Professor Stanley G. Nathenson whose numerous pioneering works laid foundation to this line of research. We thank J.S. Bezbradica and Luc Van Kaer for critical reading and advice on the manuscript as well as J.W. Yewdell for helpful discussions on the project. This work was supported by contracts (NO1 AI040079, AI040024, AI025462), research grants (HL054977, AI042284, AI061721), and core grants (CA068485, DK058404, RR024975) from the NIH and the NIAID Intramural Program.

Received for publication October 17, 2012, and accepted in revised form February 7, 2013.

Address correspondence to: Sebastian Joyce, Vanderbilt University School of Medicine, Department of Pathology, Microbiology and Immunology, A4223 Medical Centre North, 1161 21st Avenue South, Nashville, Tennessee 37232, USA. Phone: 615.322.1472; Fax: 615.343.7392; E-mail: sebastian.joyce@vanderbilt.edu.